Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.65 |
| ▸ | GAA | P10253 | 1/20 | 0.65 |
| ▸ | PTGS1 | P23219 | 5/20 | 0.60 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.51 |
| ▸ | CES2 | O00748 | 1/20 | 0.50 |
| ▸ | CES1 | P23141 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | CRHBP | P24387 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.50 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | ESRRA | P11474 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31329329 | 1.00 | MAPT (0.65) | MAPTGAAPTGS1SRD5A2CA1 | |
| SCHEMBL8374908 | 0.85 | MAPT (0.87) | MAPTGAACA1CA2CA9 | |
| SCHEMBL1173269 | 0.85 | P2RX1 (0.61) | MAPTGAAPTGS1CA1CA2 | |
| SCHEMBL28765131 | 0.82 | PTGS1 (0.57) | PTGS1SRD5A2CES2CES1HTT | |
| SCHEMBL5347968 | 0.82 | PTGS1 (0.59) | MAPTGAAPTGS1SRD5A2P2RX1 | |
| SCHEMBL3486347 | 0.81 | MAPT (0.61) | MAPTGAAPTGS1SRD5A2P2RX1 | |
| SCHEMBL3542735 | 0.81 | MAPT (0.67) | MAPTPTGS1SRD5A2CES2CES1 | |
| SCHEMBL10396396 | 0.81 | RECQL (0.53) | MAPTPTGS1SRD5A2P2RX1CES2 | |
| SCHEMBL8362275 | 0.81 | SRD5A2 (0.55) | GAAPTGS1SRD5A2CES2CES1 | |
| SCHEMBL38533242 | 0.81 | AKR1C3 (0.66) | SRD5A2CA1CA2CA9CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110606839-B | Green synthesis method of polysubstituted quinazoline derivative | 南方医科大学 | 2021-10-08 | — | — | CN | claimed |
| US-7001901-B2 | Tetrazolylpropionamides as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-02-21 | — | — | US | disclosed |
| US-20040082568-A1 | Central nervous system disorders; Alzheimer's disease | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-29 | — | — | US | disclosed |
| EP-0076017-B1 | PHENYL SUBSTITUTED PYRIDO(1,4)BENZODIAZEPINES AND INTERMEDIATES THEREFOR | A.H. ROBINS COMPANY, INCORPORATED (US) | 1990-08-16 | — | — | EP | disclosed |
| US-4668675-A | ANTIDEPRESSANTS | A. H. ROBINS COMPANY, INCORPORATED (US) | 1987-05-26 | — | — | US | disclosed |
| US-4556667-A | (2-((AMINOPYRIDINYL)AMINO)PHENYL)ARYLMETHANONE INTERMEDIATES | A. H. ROBINS COMPANY, INCORPORATED (US) | 1985-12-03 | — | — | US | disclosed |
| US-4495183-A | ANTIULCER AGENTS- GASTROLINTESTINAL DISORDERS | A. H. ROBINS COMPANY, INCORPORATED (US) | 1985-01-22 | — | — | US | disclosed |
| US-4447361-A | ANTIDEPRESSANT | A. H. ROBINS COMPANY, INC. (US) | 1984-05-08 | — | — | US | disclosed |
| EP-0076017-A2 | Phenyl substituted pyrido(1,4)benzodiazepines and intermediates therefor | A.H. ROBINS COMPANY, INCORPORATED (US) | 1983-04-06 | — | — | EP | disclosed |
| US-4313949-A | Method of producing an inhibitory effect on blood platelet aggregation | A. H. ROBINS COMPANY, INC. (US) | 1982-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082568-A1 | Central nervous system disorders; Alzheimer's disease | APP, APBA1, DNPEP | MAPT 62/4885GAA 1088/4885PTGS1 1223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.